Clarametyx
Columbus, US · Founded 2020 · Delaware corporation · 4 known investors
Clarametyx develops novel immune-enabling therapeutics targeting bacterial biofilms to modify disease progression in patients with chronic respiratory diseases.
Founders & leadership
DR
David RichardsNamed on SEC filing
PG
Peter G. KleinhenzNamed on SEC filing
ML
Michael LaymanNamed on SEC filing
CB
Chuck BramlageNamed on SEC filing
LE
Larry EdwardsNamed on SEC filing
MT
Michael Triplett IINamed on SEC filing
Board
WB
WE
Investors · 4
Reported raises · per SEC filings
Form D private placements$27.5M disclosed across 1 round · 2024
▶$27.5MraisedJan 2024 · 7 investors · BiotechnologyRule 506(b)
▶$27.5MraisedJan 2024 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David RichardsExecutive Officer
- Peter G. KleinhenzDirector
- Michael LaymanDirector
- William BaumelDirector
- Wayne EmbreeDirector
- Chuck BramlageDirector
- Larry EdwardsDirector
- Michael Triplett IIDirector
- Offering amount
- $33.1M
- Amount sold
- $27.5M
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapCelmatix6 shared keywordsCelmatix Therapeutics developed a discovery portfolio focused on women's health, including therapeutic programs for infertility, endometriosis, and ovarian aging. The company's pipeline included an oral FSH receptor agonist, a JNK inhibitor, and AMH-targeting antibodies.
Pro Matix6 shared keywordsPromatix develops bispecific antibody drug conjugates (ADCs) for solid tumours, using a proteomics-based platform to identify cancer surface marker pairs for cis-bispecific targeting. It is building a pipeline of cancer therapies with a lead program in colorectal cancer.
Aro Biotherapeutics5 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Fortis Life Sciences5 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Companies competing with Clarametyx for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Clarametyx do?
- Clarametyx develops novel immune-enabling therapeutics targeting bacterial biofilms to modify disease progression in patients with chronic respiratory diseases.
- Who are Clarametyx's investors?
- Clarametyx's investors include CincyTech, JobsOhio Ventures, Ohio Innovation Fund, Rev1 Ventures.
- How much funding has Clarametyx raised?
- Clarametyx has disclosed $27.5M raised across 1 round.
- Where is Clarametyx headquartered?
- Clarametyx is headquartered in Columbus, US.